结核分枝杆菌联合药敏试验的研究进展  

The progress of combined drug susceptibility test with Mycobacterium tuberculosis

作　　者：张琳琳[1] 杨华[2] 肖和平[2] 

机构地区：[1]苏州大学医学院临床医学系,215123 [2]上海市结核病(肺)重点实验室同济大学附属上海市肺科医院结核科

出　　处：《中国防痨杂志》2015年第1期86-89,共4页Chinese Journal of Antituberculosis

摘　　要：结核病仍然是威胁全球性的传染病，随着耐多药和广泛耐药结核分枝杆菌的出现，结核病的控制变得更加困难。为了防止结核分枝杆菌对某种药物耐药，WHO推荐结核病的治疗以几种不同的药物联合治疗为主。对于耐药结核病的治疗应根据药敏结果采取个体化治疗方案。目前的药敏试验大都是针对单药进行的，但是有时即使单药药敏试验结果是耐药，临床中与其他药物联合使用仍有较好的治疗效果，这提醒我们几种药物联合使用可能会增强其抗菌活性。当前存在一线药物耐药问题严重以及二线药物价格昂贵、毒性大等问题，因此迫切需要我们寻找新的抗结核化疗方案来控制耐药结核病的流行。在建立新的化学方案前，进行可量化的重复实验来评估方案中几种药物的联合抗菌活性是十分重要的。Tuberculosis remains a threat to global pandemic, it becomes more difficult to control TB due to the emergence of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. Preventing the resistance to a paticular drug, WHO has recommended the combined modality therapy with several drugs as the main method in the treatment of TB. Individualized treatment plan, based on the drug susceptibility results, should be taken in the treatment of drug-resistant TB. So far, the drug susceptibility test is mostly carried out for monothera py. However, in some cases, even the single drug susceptibility results are resistant, the combined modality therapy still performances better therapeutic effect, which reminds us that the combination of several drugs used in treatment may enhance its antibacterial activity. At present, because of the severe drug resistance of first line drugs and the shortcoming of second-line drugs （such as price, toxicity and so on）, we urgently need to find a new anti-TB chemotherapy to control the prevalence of drug-resistant. Before creating a new chemistry program, it is important to conduct quantified experiments repeatedly to evaluate the antimicrobial activity of the combined modality therapy.

关 键 词：结核分枝杆菌 微生物敏感性试验 

分 类 号：R520.4[医药卫生—内科学]